- Home
- LSF vs ALXO Comparison
LSF vs ALXO Comparison
Compare LSF & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | ALXO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 68.3M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LSF | ALXO |
|---|---|---|
| Price | $2.70 | $2.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $12.00 | $3.42 |
| AVG Volume (30 Days) | 64.0K | ★ 998.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | 31.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,295,137.00 | N/A |
| Revenue This Year | $15.87 | N/A |
| Revenue Next Year | $14.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.50 | N/A |
| 52 Week Low | $1.98 | $0.41 |
| 52 Week High | $7.94 | $2.66 |
Technical Indicators
Market Signals| Indicator | LSF | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 39.41 | 50.20 |
| Support Level | $2.46 | $1.41 |
| Resistance Level | $2.76 | $2.27 |
| Average True Range (ATR) | 0.21 | 0.25 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 12.90 | 13.08 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.